Skip to main content
Equibles
ALDX logo

ALDX · Aldeyra Therapeutics, Inc.

Track ALDX — free

Use ALDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.96 -0.21 (-18.03%) At close · Oct 5
Rebalance outlook locked
Market Cap
$70.88M
Shares
60.33M
Volume · Oct 5 7.03M Avg daily vol (3M) 1.04M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.17 Open$1.31 Day$1.15–1.31 52W close$1.16–5.74 Avg vol 30d917K Short int3.6M · 6.0% float · 4.9d Short vol56% Last earningsMay 4, 2023 DataJan 2020–Oct 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026
Q4 2022 earnings call transcript
call held Mar 9, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$23.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.5%
Year over year · more shares
Price change (1Y)
-78.0%
Trailing year
Short interest
6.0%
Latest settlement · 4.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.59
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −56%
below
Price vs 50-day avg −20%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −21%
trailing
6-month return −35%
trailing
YTD return −77%
this year
Relative strength −47%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.97% of float · ▲ +15.5% MoM · 4.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
107 holders — mid 3-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Strong
EPS growth +40%
Y/Y
Free cash flow $-33.3M
Balance sheet $54.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 115%
annualized · 1-yr
Max drawdown −80%
past year
ATR 8.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−56% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.97% of float · ▲ +15.5% MoM · 4.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
107 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $6
vs 200-day avg -56% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALDX
Aldeyra Therapeutics, Inc.
this stock
$70.88M -77.4% — — 6.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
107
% held
61.7%
Net QoQ
-1.1M sh
Top holder
Knoll Capital Management,…
Held Float
View
Held by Funds
Fund positions
60
View
Short & Settlement
Short Interest Rising
Shares short
3.6M
Days to cover
4.9d
Change
+482.6K sh
View
Short Volume
Short vol %
56%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$5.2K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
49.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-33.8M
EPS diluted
$-0.56
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 29, 2026
This year
13
View
Proposed Sales
Value
$116.1K
Shares
22.1K
Filed
Aug 12, 2025
View
Earnings & Events
Webcasts
Last webcast
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
ALDX -2.9% -21.0% -35.0% -4.9% -77.4%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -2.7% -20.5% -47.2% -5.8% -90.3%
Key facts CIK 1341235 CUSIP 01438T106 13F (30d) 2 filings 2 filers Visit website Investor relations